A substantial proportion of atrial fibrillation patients initiating direct oral anticoagulants
(DOAC) are vitamin K antagonists (VKA)‐experienced, for example switchers from VKA to …

Thromboembolic events (TEE) associated with atrial fibrillation (AF) are highly recurrent and
usually severe, causing permanent disability or, even, death. Previous data consistently …

Objectives We identified factors associated with thromboembolic and bleeding events in two
contemporary cohorts of anticoagulated patients with atrial fibrillation (AF), treated with …

Atrial fibrillation is a commonly encountered arrhythmia associated with increased risk for
thromboembolic events. Anticoagulation is necessary to decrease the risk of ischemic …

Background The introduction of non-vitamin K antagonist oral anticoagulants (NOACs) has
been a major advance for stroke prevention in atrial fibrillation (AF). Patients and clinicians …

Background—Novel oral anticoagulants (NOACs) have been proposed as alternatives to
vitamin K antagonists for the prevention of stroke and systemic embolism in patients with …

Purpose To report the use of direct oral anticoagulants (DOACs) for stroke prevention in
patients with atrial fibrillation in Scotland and advocate the standardisation of drug utilisation …

Aims The aim of this study was to compare the risk of stroke or systemic embolism (SE) and
major bleeding in patients with atrial fibrillation (AF) using dabigatran, rivaroxaban, and …

Direct oral anticoagulants (DOACs) have been demonstrated to be more effective and safer
than vitamin-K antagonist (VKA) for stroke prevention in patients with nonvalvular atrial …

Objectives This study evaluated the comparative effectiveness of vitamin K antagonists
(VKAs), direct thrombin inhibitors (DTIs) and factor Xa inhibitors (FXaI) in patients with atrial …